A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )
ClinicalTrials.gov Identifier:
NCT01655056
First received: July 30, 2012
Last updated: June 24, 2013
Last verified: July 2012
  Purpose

The study aims to investigate the effect of YM150 and to compare gender and ethnic differences in healthy Caucasian and Japanese male and female subjects.


Condition Intervention Phase
Pharmacokinetics
Pharmacodynamics
Healthy Subjects
Caucasian
Japanese
Drug: YM150
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YM150 in Healthy Caucasian and Japanese Male and Female Subjects

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG), clinical safety laboratory and adverse events [ Time Frame: Day -21 - Day 25 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pharmacokinetics (PK) and pharmacodynamics (PD) of YM150 assessed by plasma and urine concentrations [ Time Frame: Day 1 - Day 11 ] [ Designated as safety issue: No ]
    Cmax (Maximum concentration), tmax (Time to attain Cmax), t1/2 (Apparent terminal elimination half-life), Vz/F (Apparent volume of distribution), CL/F (Apparent total body plasma clearance), CLR (Renal clearance), PTmax (Maximum Prothrombin time), aPTTmax (Maximum activated partial thromboplastin time), AUClast (AUC until last sample taken), AUC0-inf (AUC extrapolated until infinity), AUC0-24h (AUC between time 0 and 24h), Aelast (Amount excreted in urine until last sample), Ae0-inf (Amount excreted in urine extrapolated until infinity), %Excrlast, %Excr0-inf, %Excr0-24h and Ae0-24h (Amount excreted in urine between time 0 and 24h)

  • Gender effects on the PK and PD of YM150. [ Time Frame: Day 1 - Day 11 ] [ Designated as safety issue: No ]
    Cmax, tmax, t1/2, Vz/F, CL/F, CLR, PTmax, aPTTmax, AUClast, AUC0-inf, AUC0-24h, Aelast, Ae0-inf, %Excrlast, %Excr0-inf, %Excr0-24h and Ae0-24h


Enrollment: 82
Study Start Date: June 2006
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: low male dose
Japanese and Caucasian males
Drug: YM150
oral
Other Name: darexaban
Drug: Placebo
oral
Experimental: medium male dose
Japanese and Caucasian males
Drug: YM150
oral
Other Name: darexaban
Drug: Placebo
oral
Experimental: high male dose
Japanese and Caucasian males
Drug: YM150
oral
Other Name: darexaban
Drug: Placebo
oral
Experimental: high female dose
Japanese and Caucasian females
Drug: YM150
oral
Other Name: darexaban
Drug: Placebo
oral
Experimental: highest male dose
Japanese and Caucasian males
Drug: YM150
oral
Other Name: darexaban
Drug: Placebo
oral

Detailed Description:

Each dose group consists of a cohort of 8 Caucasian and 8 Japanese male subjects to be randomized such that 6 subjects of each race receive active treatment and 2 subjects of each race receive matching placebo. The highest tolerated dose is repeated with a cohort of 8 Caucasian and 8 Japanese female subjects, unless emerging safety and PK information justifies higher dose levels or require additional female dose groups.

Each subject is administered a single dose YM150 or placebo on Day 1 followed by multiple doses of YM150 or placebo once daily on Days 3 to 9.

  Eligibility

Ages Eligible for Study:   20 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Japanese subjects had to be born in Japan, have Japanese parents, have Japanese passports, have been resident in the West for no longer than 10 years or not at all and have a Japanese lifestyle (food habit)

Caucasian subjects:

  • Body weight:

    • Males: 60-100 kg
    • Females: 50-90 kg
  • BMI: 18.0-27.0 kg/m2 (males and females)

Japanese subjects:

  • Body weight:

    • Males: 50-80 kg
    • Females: 40-70 kg
  • BMI: 18.0-27.0 kg/m2 (males and females)

Exclusion Criteria:

  • Female subject of child-bearing potential, not practicing adequate methods to prevent pregnancies, like abstinence or double barrier methods (e.g. condom in combination with a spermicidal crème)
  • Female subject showing a positive pregnancy test
  • Lactating mother or woman with an intention of pregnancy
  • Known or suspected hypersensitivity to YM150 or any of the constituents of the formulations used
  • History of and/or any sign or symptom indicating current abnormal hemostasis or blood dyscrasia, including but not limited to neutropenia, thrombocytopenia, thrombocytopathy, thromboasthenia, hemophilia, Von Willebrand's disease, and vascular purpura, bleeding gums, or frequent nose bleeding
  • Family history of congenital vascular malformation (e.g. Marfan's Syndrome) and/or bleeding disorder (e.g. hemophilia, Von Willebrand's disease, Christmas disease)
  • History of peptic ulcer or of any other organic lesion susceptible to bleed
  • PT or aPTT at the screening visit outside the normal range
  • Any surgical intervention (including tooth extraction) or trauma within the last 3 months preceding the initiation of the study
  • Any clinically significant history of asthma, eczema, any other clinically significant allergic condition or previous severe hypersensitivity to any other drug
  • Any clinically significant upper gastro-intestinal symptoms likely to interfere with the absorption of the drug
  • History or presence of any cardiovascular disease or disorder
  • History of a clinically significant ECG abnormality
  • Any clinically relevant history of other disease or disorder - gastrointestinal, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic
  • Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG, and clinical laboratory tests
  • Abnormal heart rate and blood pressure measurements at the screening visit as follows: heart rate <40 or >90 bpm; mean systolic blood pressure <95 or >160 mmHg; mean diastolic blood pressure <40 or >95 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min)
  • Regular use of any prescribed or OTC drugs in the 4 weeks prior to admission to the clinical unit OR any use of such drugs in the 2 weeks prior to admission to the clinical unit
  • History of drug abuse at any time, OR any use of drugs of abuse within 3 months prior to admission to the clinical unit
  • Participation in any clinical study within 3 months, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study
  • History of drinking more than 21 units of alcohol per week (1 unit = 270 ml of beer or 40 ml of spirits or 125 ml of wine) within 3 months prior to admission to the clinical unit
  • History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit
  • Subject, who is anti-HAV (IgM), anti-HCV, HBsAg or HIV-1 or -2 positive
  • Donation of blood (>400 ml) or blood products within 3 months prior to admission to the clinical unit or plasmapheresis within 4 weeks prior to admission to the clinical unit
  • Employees of the Astellas Group or CRO involved in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01655056

Locations
Germany
FOCUS Clinical Drug Development GmbH
Neuss, Germany, 41460
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Investigators
Study Chair: Clinical Study Manager Astellas Pharma Europe B.V.
  More Information

Additional Information:
No publications provided

Responsible Party: Astellas Pharma Inc ( Astellas Pharma Europe B.V. )
ClinicalTrials.gov Identifier: NCT01655056     History of Changes
Other Study ID Numbers: 150-CL-006, 2004-004935-72
Study First Received: July 30, 2012
Last Updated: June 24, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Astellas Pharma Inc:
Pharmacokinetics
Pharmacodynamics
Phase 1
YM150
Dose-escalating
Ethnicity
Caucasian
Japanese

ClinicalTrials.gov processed this record on August 26, 2014